Biodistribution of a monoclonal antibody-methotrexate conjugate (791T/36-MTX) in patients with colorectal cancer

✍ Scribed by K. C. Ballantyne; A. C. Perkins; M. V. Pimm; M. C. Garnett; Jane A. Clegg; N. C. Armitage; R. W. Baldwin; J. D. Hardcastle

• Publisher: John Wiley and Sons
• Year: 1988
• Tongue: French
• Weight: 547 KB
• Volume: 41
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910410724

✦ Synopsis

The monoclonal antibody (MAb) 791T/36 which has previously been shown to localise in colorectal cancer has been conjugated to methotrexate (MTX) for potential use as a chemotherapeutic agent in malignant disease. To examine its biodistribution and tumour localisation, 16 patients with primary colorectal cancer were injected intravenously with '3'I-labelled 791T/36-MTX conjugate and imaged using a gamma camera after 48-72 hr. Serial blood samples were taken to determine the levels of circulating conjugate and samples of tumour and normal colon were assayed for uptake of radioactivity. Whole body biodistribution, visualised by gamma scintigraphy, and blood clearance of both the antibody and drug moieties of 791T/36-MTX were similar to that previously found with unconjugated antibody. Assays of tissue radioactivity showed positive tumour uptake of drug-antibody conjugate (T:NT> l.9:l) in 13/15 primary tumour specimens (median T:NT = 2.9:l). These studies indicate that 79 I T/36-MTX conjugates may have potential in the treatment of metastatic colorectal carcinoma.